References
- Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. J Am Med Assoc 2007;298:655–69.
- Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776–84.
- Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005;28:144–52.
- Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94.
- Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036–43.
- Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203–16.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
- Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
- Puechal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis. Results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 2012;64:331–9.
- Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–8.
- Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458–66.
- Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol 2012;41:116–19.
- Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156–68.
- Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394–400.
- Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011;63:2209–14.